Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
KLOW: The Complete Guide
KLOW extends GLOW with a fourth compound, KPV, addressing chronic inflammation rather than driving repair directly. This guide covers whether you actually need KLOW over the simpler GLOW or Wolverine blends, the real ratio consensus across vendors, and the dose math for a four-compound combination — without inflating the evidence beyond what exists.
This content is intended for research and educational purposes only. All compounds discussed on AethonLabs.ca are sold strictly for research use and are not intended for human consumption. Always consult a qualified healthcare professional before beginning any new health protocol.
KLOW is the most comprehensive healing blend in the research peptide space — four compounds in one vial, each targeting a different piece of the tissue repair and inflammation puzzle. If you’ve read our guide on BPC-157 and TB-500, KLOW is the natural next step: the same Wolverine healing foundation, with two additional compounds layered on top for skin and connective tissue support and targeted inflammation control. This guide covers what’s inside, how the four components work together, what the research shows, and the practical details before you start.
What It Is
KLOW is a four-peptide blend combining:
- BPC-157 (10mg) — tissue repair and angiogenesis
- TB-500 (10mg) — cell migration and anti-inflammatory immune modulation
- GHK-Cu (50mg) — collagen synthesis and copper-dependent tissue remodeling
- KPV (10mg) — targeted anti-inflammatory action
Total blend: 80mg per vial
Each compound is well studied independently. What makes KLOW distinct is that the four work through genuinely different mechanisms rather than overlapping redundantly — meaning the blend is designed to address multiple sides of tissue repair and inflammation simultaneously, rather than just stacking more of the same effect.
If you’re already familiar with our Wolverine blend (BPC-157 + TB-500), KLOW is the fullest expression of that same family — Wolverine plus GHK-Cu plus KPV, all in a single vial.
How It Works
BPC-157 drives angiogenesis (new blood vessel formation) and growth factor modulation. Research has shown it elevates VEGF expression in healing tissue and is one of the only compounds consistently effective across tendon, ligament, muscle, bone, and gastrointestinal healing models in comparative reviews.
TB-500 drives cell migration and shifts the inflammatory environment. It appears to shift macrophage polarization from pro-inflammatory M1 phenotypes toward anti-inflammatory M2 phenotypes — moving the immune response at an injury site from “attack” toward “repair” — while also supporting angiogenesis through a separate, complementary pathway to BPC-157.
GHK-Cu is a naturally occurring copper-binding tripeptide that the body produces in declining amounts with age — plasma concentrations measure around 200 ng/mL at age 20 and drop to roughly 80 ng/mL by age 60. Its primary mechanism is copper-mediated activation of lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin fibers into a stable structural matrix. Without adequate copper delivery, newly synthesized collagen remains poorly organized. GHK-Cu also modulates matrix metalloproteinases (MMPs) — clearing damaged collagen while protecting healthy tissue — and genomic research has shown it influences expression of more than 4,000 human genes tied to repair and regenerative pathways. A 2026 clinical dataset found a mean 28% increase in subdermal collagen and elastin density after three months, with the top quartile of participants showing a 51% improvement.
KPV is a tripeptide (lysine-proline-valine) derived from alpha-MSH that works through a mechanistically distinct pathway from the other three: direct inhibition of NF-κB, the master regulator of the inflammatory cascade inside cells. Unlike broader immune suppressants, KPV appears to dampen inflammation at the source without systemic immune suppression and without the melanocortin receptor activation that would otherwise cause pigmentation effects. It has been studied for both gut inflammation and skin inflammation through the same core mechanism.
Together: BPC-157 and TB-500 drive the structural and cellular repair process, GHK-Cu provides the copper and signaling needed to properly rebuild and organize the resulting collagen matrix, and KPV controls the inflammatory cascade that, left unchecked, can slow or complicate the entire repair process.
What the Research Shows
No human trial has tested this exact four-peptide combination together. Each individual compound has its own research base, of varying depth and quality:
BPC-157 and TB-500 have extensive preclinical data — a 2025 systematic review covered 36 studies, 35 of them preclinical — with accelerated tendon healing of roughly 60-80% in animal models. Only a handful of human pilot studies exist for either compound individually.
GHK-Cu has notably stronger human evidence than the other three components. The 2026 ultrasound-measured collagen density study referenced above is real clinical data, which sets it apart from BPC-157, TB-500, and KPV in terms of evidence maturity. It’s one of the few compounds in this space where measurable human outcomes exist beyond animal models.
KPV has a deep but almost entirely preclinical and early-phase evidence base — animal models of colitis and dermatitis, plus emerging Phase II human trial data specifically in dermatological conditions. Notably, KPV is currently under active regulatory review: the FDA’s Pharmacy Compounding Advisory Committee scheduled a formal evaluation of KPV (alongside BPC-157, TB-500, and MOTS-c) for July 23, 2026, considering whether to add it to the 503A Bulk Drug Substances List. This reflects growing institutional interest in formalizing these compounds and is a development worth monitoring.
The combination itself is a community-driven formulation built on complementary individual mechanisms rather than a tested clinical protocol in its own right.
Community Protocols
| Daily Dose | Units | BPC-157 | TB-500 | GHK-Cu | KPV | Cycle Length |
|---|---|---|---|---|---|---|
| 2mg | 5 units | 250mcg | 250mcg | 1.25mg | 250mcg | 4–12 weeks |
| 4mg | 10 units | 500mcg | 500mcg | 2.5mg | 500mcg | 4–12 weeks |
| 6mg | 15 units | 750mcg | 750mcg | 3.75mg | 750mcg | 4–12 weeks (longer for chronic conditions) |
The standard 10-unit dose (4mg total) delivers each peptide within its established standalone dosing range — 500mcg of BPC-157, TB-500, and KPV respectively, and 2.5mg of GHK-Cu. This makes 10 units the natural reference point for most research protocols.
Inject close to the area of interest when possible, or use standard subcutaneous administration for systemic distribution. Cycle length for active injury or skin and connective tissue research is commonly reported in the 4-6 week range, though some extend longer given GHK-Cu’s slower-developing collagen remodeling effects — the clinical data above showed continued improvement out to three months.
Best for:
- Tissue injury and recovery
- Skin and connective tissue support
- Inflammation control
- Post-procedure recovery
When to Use It
KLOW’s broader mechanism profile makes it relevant for a wider range of research applications than the Wolverine blend alone:
- Tissue injury research where both repair speed and final tissue quality are of interest, given GHK-Cu’s role in collagen structuring
- Skin and connective tissue research, an application BPC-157 and TB-500 alone don’t directly address
- Research contexts where inflammation control is a specific variable of interest, given KPV’s distinct NF-κB mechanism
- Post-procedure or post-injury recovery research where multiple repair pathways — vascular, cellular, structural, and inflammatory — are all relevant simultaneously
When Not to Use It
- Active bleeding disorders or anticoagulant use — the same caution applies as with the Wolverine blend given the angiogenic mechanisms involved
- Known allergy to any of the four components
- Pregnancy or breastfeeding
- Athletic competition subject to drug testing — BPC-157 and TB-500 are both prohibited or monitored substances; while GHK-Cu is not on the WADA Prohibited List, the blend as a whole should be treated as off-limits for tested athletes
- Research specifically isolating a single mechanism — because KLOW combines four distinct pathways, sourcing the individual peptides separately is more appropriate if your research design requires isolating a specific compound’s effect
Reconstitution
KLOW ships as a pre-mixed lyophilized blend, so you’re reconstituting one vial rather than four separate compounds.
Recommended solvent: Bacteriostatic water (BAC water). Although KLOW contains TB-500 — which requires acetic acid when reconstituted as a standalone powder — the pre-mixed lyophilized blend integrates all four components during the freeze-drying process. In this combined form, BAC water dissolves the blend reliably and is the standard recommendation across the research community. Acetic acid is not required for the pre-mixed vial.
Recommended volume: 2mL, giving a concentration of 40mg/mL. This produces the cleanest syringe math of any reconstitution option — 10 units equals exactly 4mg total blend, with each component landing squarely within its established standalone dosing range.
Reconstitution steps:
- Wipe both vial tops with alcohol swabs and allow to air dry
- Draw 2mL of bacteriostatic water into your syringe
- Insert the needle into the KLOW vial and aim at the glass wall — let the water trickle down slowly rather than squirting directly onto the powder
- Gently swirl until completely dissolved. Do not shake.
- The GHK-Cu component may produce a very faint blue-green tint — this is normal for a copper complex and is not a sign of contamination
- Label with reconstitution date and concentration (40mg/mL)
- Refrigerate immediately at 2–8°C. Use within 28 days.
Reconstitution guide:
| Vial Size | Solvent | Volume | Concentration | 1 Unit = | 10 Units = |
|---|---|---|---|---|---|
| 80mg total blend | BAC water | 2mL | 40mg/mL combined | 400mcg | 4mg |
Per-compound breakdown at standard doses:
| Total Dose | Units | BPC-157 | TB-500 | GHK-Cu | KPV |
|---|---|---|---|---|---|
| 2mg | 5 units | 250mcg | 250mcg | 1.25mg | 250mcg |
| 4mg | 10 units | 500mcg | 500mcg | 2.5mg | 500mcg |
| 6mg | 15 units | 750mcg | 750mcg | 3.75mg | 750mcg |
See our full reconstitution guide for general technique and supplies.
Tips & Tricks
The GHK-Cu tint is normal. A faint blue-green tint in the reconstituted solution is expected — GHK-Cu is a copper complex and this colour is characteristic of the compound in solution. It is not contamination.
Do not squirt water directly onto the powder. Aim the needle at the glass wall and let the liquid trickle down slowly. All four peptides in KLOW are fragile molecular chains — aggressive force during reconstitution can reduce potency.
Never shake the vial. Shaking creates foam at the air-liquid interface which can denature peptide molecules. Gentle swirling only.
10 units is your reference point. At 40mg/mL, 10 units delivers exactly 4mg total blend — a clean, practical dose that puts every component within its effective research range. Build your protocol around multiples of 10 units for the simplest possible dosing math.
Track multiple outcome markers, not just one. Because KLOW is designed to influence several mechanisms simultaneously, researchers commonly track more than a single metric — both pain and mobility (BPC-157 and TB-500 territory) and visible skin or tissue quality changes (GHK-Cu territory) — to get a fuller picture of which components are driving which observed effects.
Consider individual components if isolating variables matters. If your research specifically needs to determine which compound is responsible for an observed effect, running BPC-157, TB-500, GHK-Cu, and KPV separately will give you cleaner data than the pre-mixed blend.
Watch the regulatory landscape on KPV. Given the July 2026 FDA review covering KPV, BPC-157, TB-500, and MOTS-c, this is a space worth monitoring — the regulatory status of these compounds could shift meaningfully within the next year.
Storage
- Lyophilized (unreconstituted): 2–8°C, away from light. Stable 12+ months. Can be frozen for longer storage.
- Reconstituted: Refrigerate at 2–8°C. Use within 28 days. Do not freeze after reconstitution. Store upright and away from direct light.
Where to Go From Here
- Wolverine: BPC-157 & TB-500 Complete Guide — the foundational two-peptide combination KLOW builds on
- Reconstitution Guide — full step-by-step technique and supplies
- How to Read a COA — understanding purity and identity testing for multi-compound blends
AethonLabs.ca sells all compounds for research and educational purposes only. Nothing on this site constitutes medical advice. Products are not intended for human consumption. Consult a qualified healthcare professional before beginning any new protocol.